Opinercept (Research-Grade) is a research-grade biosimilar monoclonal antibody targeting CD2. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Tumor necrosis factor (TNFa/TNF-alpha) is a ~25 kDa protein. Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Up-regulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective. TNFa is the therapeutic target of adalimumab (Humira).
Product Name:
Opinercept (Research-Grade)
SKU:
GXBS01207
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Target:
C-domain 1
Isotype:
Fusion - [TNFRSF1B (tumor necrosis factor receptor (TNFR) superfamily member 1B, TNFBR, p75, CD120b)]2 - IGHG1 Fc (Fragment constant)
Reactivity:
Human
Applications:
ELISA, Functional assay, Research in vivo
Synonyms:
ENIA11, TNFalphaR-Fc, TuNEX, 2055118-96-0
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4.
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
